RAF/MEK钳合剂avutometinib联合FAK抑制剂在低级别浆液性卵巢癌中的临床前疗效
本研究利用3例低级别浆液性卵巢癌(LGSOC)患者来源的肿瘤异种移植模型(PDX),评估avutometinib联合VS-4718的临床前疗效。全外显子测序显示3例LGSOC均为KRAS野生型,OVA(K)250 PDX存在PTK2/PTK2B功能获得性突变。avutometinib联合VS-4718自第9天起即表现出强于对照组的肿瘤生长抑制(p<0.002),且显著延长生存期。
要点
- 3例LGSOC全外显子测序均为KRAS野生型,OVA(K)250 PDX携带PTK2/PTK2B功能获得性突变。
- avutometinib联合VS-4718自第9天起较对照组显著抑制OVA(K)250 PDX肿瘤生长(p<0.002)。
- 60天时avutometinib单药及联合组小鼠均存活,对照组中位生存20天,VS-4718组35天(p<0.0001)。
核心结论
- avutometinib单药及更大程度上与FAK抑制剂VS-4718联合,在KRAS野生型LGSOC-PDX中显示出有前景的体内活性。
- 这些数据支持正在进行的注册导向研究RAMP201/NCT04625270。
研究设计与样本
- 临床前研究:对3例患者来源的LGSOC(OVA(K)250、PERIT(M)17和A(PE)148)进行全外显子测序以评估基因指纹。
- 将OVA(K)250组织成功异种移植到雌性CB17/lcrHsd-Prkdc/SCID小鼠建立PDX模型。
- 动物接受对照、avutometinib、VS-4718或avutometinib/VS-4718治疗,每日一次,口服灌胃,给药5天停2天。
- 利用avutometinib±defactinib处理的LGSOC肿瘤样本通过蛋白质印迹进行离体机制研究。
主要发现
- 全外显子测序显示3例LGSOC均为KRAS野生型。
- OVA(K)250 PDX显示PTK2和PTK2B基因功能获得性突变(GOF),以及ADRB2杂合性缺失,可能对FAK和RAF/MEK抑制敏感。
- 在OVA(K)250 PDX中,avutometinib/VS-4718联合自第9天起较对照组表现出强肿瘤生长抑制(p<0.002)。
- 60天时,avutometinib单药组和avutometinib/VS-4718联合组小鼠仍存活;对照组中位生存20天,VS-4718组中位生存35天(p<0.0001)。
- 蛋白质印迹显示,OVA(K)250暴露于avutometinib、FAK抑制剂defactinib及其联合后,磷酸化FAK(p-FAK)及p-ERK均降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Low-grade-serous-ovarian-carcinoma (LGSOC) is characterized by a high recurrence rate and limited therapeutic options. About one-third of LGSOC contains mutations in MAPK pathway genes such as KRAS/NRAS/BRAF. Avutometinib is a dual RAF/MEK inhibitor while defactinib and VS-4718 are focal-adhesion-kinase-inhibitors (FAKi). We determined the preclinical efficacy of avutometinib±VS-4718 in LGSOC patient-derived-tumor-xenografts (PDX). METHODS: Whole-exome-sequencing (WES) was used to evaluate the genetic fingerprint of 3 patient-derived LGSOC (OVA(K)250, PERIT(M)17 and A(PE)148). OVA(K)250 tissue was successfully xenografted as PDX into female CB17/lcrHsd-Prkdc/SCID-mice. Animals were treated with either control, avutometinib, VS-4718, or avutometinib/ VS-4718 once daily five days on and two days off through oral gavage. Mechanistic studies were performed ex vivo using avutometinib±defactinib treated LGSOC tumor samples by western blot. RESULTS: WES results demonstrated wild-type KRAS in all 3 LGSOC. OVA(K)250 PDX showed gain-of-function mutations (GOF) in PTK2 and PTK2B genes, and loss-of-heterozygosity in ADRB2, potentially sensitizing to FAK and RAF/MEK inhibition. The combination of avutometinib/ VS-4718 demonstrated strong tumor-growth inhibition compared to controls starting at day 9 (p < 0.002) in OVA(K)250PDX. By 60 days, mice treated with avutometinib alone and avutometinib/VS-4718 were still alive; compared to median survival of 20 days in control-treated mice and of 35 days in VS-4718-treated mice (p < 0.0001). By western-blot assays exposure of OVA(K)250 to avutometinib, FAKi defactinib and their combination demonstrated decreased phosphorylated FAK (p-FAK) as well as decreased p-ERK. CONCLUSION: Avutometinib, and to a larger extent its combination with FAK inhibitor VS-4718, demonstrated promising in vivo activity against a KRAS wild-type LGSOC-PDX. These data support the ongoing registration-directed study (RAMP201/NCT04625270).
引用
- McNamara B, Demirkiran C, Hartwich TMP, et al. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecol Oncol. 2024. PMID: 38493021. doi:10.1016/j.ygyno.2024.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。